Skip to main content
RaQualia Pharma Inc. logo

RaQualia Pharma Inc. — Investor Relations & Filings

Ticker · 4579 ISIN · JP3967150008 T Professional, scientific and technical activities
Filings indexed 89 across all filing types
Latest filing 2025-03-26 AGM Information
Country JP Japan
Listing T 4579

About RaQualia Pharma Inc.

https://www.raqualia.com/en/index.html

RaQualia Pharma Inc. is a research and development-focused pharmaceutical company that specializes in the discovery and development of innovative small molecule compounds. The company's primary activities involve conducting exploratory research to identify novel drug candidates and advancing them through preclinical and clinical studies. Its business model centers on creating value by out-licensing the intellectual property of these compounds to other pharmaceutical companies for final development and commercialization. A key product originating from its research is tegoprazan (K-CAB®), a potassium-competitive acid blocker used for treating gastroesophageal reflux disease and other acid-related conditions.

Recent filings

Filing Released Lang Actions
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted because resolutions were passed at the Annual General Meeting (定時株主総会) held on March 25, 2025, in accordance with financial regulations. Section 2 details the resolutions, which concern the election of directors and audit committee members. This content—reporting the results of shareholder votes on board appointments following an AGM—directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the core purpose is reporting the *results* of the vote, not providing the AGM presentation materials (AGM-R).
2025-03-26 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document text contains Japanese characters and includes the header "有価証券報告書(通常方式)" which translates to 'Securities Report (Normal Method)'. It also explicitly mentions '金融商品取引法' (Financial Instruments and Exchange Act) and confirms the appropriateness of the '有価証券報告書' (Securities Report) for the fiscal year ending December 31, 2024. In the context of Japanese regulatory filings, a comprehensive annual report filed under the Financial Instruments and Exchange Act is equivalent to the US SEC's 10-K filing. Given the content is the confirmation/attestation regarding the annual securities report, it strongly points to the full annual filing itself, which maps best to the '10-K' category for comprehensive annual performance reporting, even though the specific document shown is a confirmation statement attached to it. The length is short, but the content is about the core annual filing. FY 2024
2025-03-26 Japanese
内部統制報告書-第17期(2024/01/01-2024/12/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and within the table structure. It references the Financial Instruments and Exchange Act (金融商品取引法第24条の4の4第1項) and details the scope, criteria, and conclusion of the assessment of internal controls over financial reporting as of the fiscal year-end (2024年12月31日). This content aligns perfectly with the requirements for an Audit Report / Information filing, specifically concerning internal controls, which falls under the 'AR' category as defined, distinguishing it from a full Annual Report (10-K) or a simple Earnings Release (ER).
2025-03-26 Japanese
有価証券報告書-第17期(2024/01/01-2024/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, management discussion, and corporate information for the fiscal year ending December 31, 2024. It is not an announcement or a summary, but the full statutory filing. FY 2024
2025-03-26 Japanese
有価証券届出書(参照方式)
Capital/Financing Update Classification · 98% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and is filed with the "東海財務局長" (Director of the Tokai Local Finance Bureau) on March 21, 2025. It details the issuance of new shares (2,592,100 shares of common stock) via a third-party allotment ("第三者割当") to HK inno.N Corporation, including the offering price, total amount to be raised (1,029,063,700 JPY), and the intended use of proceeds (R&D investment). This structure—a formal filing detailing a public offering or issuance of securities—corresponds directly to the definition of a filing related to capital/financing activities, specifically a registration statement for a stock issuance. In the provided list, the most appropriate code for a filing detailing the issuance of securities for fundraising is "CAP" (Capital/Financing Update), as it explicitly covers company fundraising and capital structure changes, which this document details comprehensively.
2025-03-21 Japanese
臨時報告書
Board/Management Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 ("提出理由") that it is being filed based on the Financial Instruments and Exchange Act regulations because the Board of Directors resolved on a change in the Representative Director on December 13, 2024. Section 2 details the change in the Representative Director (name, old/new position, effective date). This content directly corresponds to an announcement regarding changes in senior management, which maps to the 'Board/Management Information' category (MANG). Although it is a regulatory filing, MANG is the more specific classification for management changes.
2024-12-13 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.